Karl Nadolsky, DO
Endocrinology, Diabetes & Metabolism · Holland, MINPI 1053567743
Payments from drug & device makers
Across 646 payments — averaging $42.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$8K
- Sanofi-aventis U.S. LLC$6K
- Novo Nordisk$5K
- Amryt Pharma Holdings Ltd$2K
- Boehringer Ingelheim$1K
- Xeris Pharmaceuticals, Inc.$825
- plus $5K from 31 others
What the payments were for
- Consulting fees$1,7586%
- Speaking & faculty fees$13,12147%
- Travel & lodging$8983%
- Food & beverage$11,53942%
- Education$4262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 24 | $8,013 |
| Sanofi-aventis U.S. LLC | 66 | $6,207 |
| Novo Nordisk | 305 | $5,232 |
| Amryt Pharma Holdings Ltd | 4 | $1,812 |
| Boehringer Ingelheim | 42 | $1,049 |
| Xeris Pharmaceuticals, Inc. | 15 | $825 |
| Lilly USA, LLC | 40 | $676 |
| Amgen(2 entities) | 27 | $652 |
| Dexcom, Inc. | 21 | $594 |
| Medtronic(2 entities) | 7 | $347 |
| Madrigal Pharmaceuticals | 13 | $327 |
| Ascendis Pharma Endocrinology Inc | 8 | $266 |
| Insulet Corporation | 6 | $210 |
| Tandem Diabetes Care, Inc. | 9 | $174 |
| Valeritas, Inc. | 3 | $163 |
| Abbott | 6 | $154 |
| Senseonics, Incorporated | 3 | $133 |
| Antares Pharma, Inc. | 6 | $102 |
| Bayer | 4 | $89 |
| Astellas Pharma US Inc | 4 | $86 |
| Rhythm Pharmaceuticals, Inc. | 4 | $78 |
| Radius Health, Inc. | 4 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $51 |
| AbbVie | 1 | $50 |
| AstraZeneca(2 entities) | 3 | $49 |
| Kvk-tech, Inc. | 1 | $42 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Sequel Med Tech, LLC | 2 | $40 |
| Pfizer | 2 | $36 |
| Chiesi USA, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $31 |
| Echosens North America, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$7,719
- TZIELD$4,726
- MYCAPSSA$1,783
- GVOKE HYPOPEN$600
- DEXCOM G6 TRANSMITTER$234
- SOLIQUA 100/33$210
- V-GO$139
- Yorvipath$125
- Omnipod$125
- TEPEZZA$123
- MINIMED 780G$122
- JARDIANCE$119
- TOUJEO$117
- REZDIFFRA$109
- Minimed 670G System$107
How this compares
$27,742 in reported general payments places this provider in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 374 | $497,549 |
| JardianceEmpagliflozin | 227 | $241,319 |
| OzempicSemaglutide | 168 | $240,354 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $111,723 |
| TrulicityDulaglutide | 60 | $71,738 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 48 | $59,210 |
| LyumjevInsulin Lispro-Aabc | 37 | $49,097 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 46 | $39,227 |
| KerendiaFinerenone | 27 | $35,592 |
| SynjardyEmpagliflozin/Metformin Hcl | 43 | $34,494 |
| FarxigaDapagliflozin Propanediol | 24 | $32,486 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $27,643 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $24,683 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $22,799 |
| XyostedTestosterone Enanthate | 11 | $14,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $676 | $630,549512 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $1,049 | $335,023318 claims |
| Novo NordiskOzempic, Novolog | $5,232 | $246,448185 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $6,207 | $39,22746 claims |
| BayerKerendia | $89 | $35,59227 claims |
| AstraZenecaFarxiga | $49 | $32,48624 claims |
| Antares Pharma, Inc.Xyosted | $102 | $14,88611 claims |
| AbbVieSynthroid | $50 | $1,79725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Holland
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.